Abstract
A prescription-event monitoring (PEM) study has confirmed that fluconazole, a bis-triazole oral antifungal drug, is a safe and effective treatment for vaginal candidiasis. Useful information was available on 15,015 questionnaires returned by general practitioners. The events were compared with those recorded in PEM studies of itraconazole and 31 other drugs in a total of more than 330,000 patients.
The frequency of events in the study of itraconazole was almost identical. Upper respiratory tract and genitourinary infections were reported with above-average frequency but the relationship was with the disease being treated rather than the drug itself. No serious adverse effects were recorded with an unacceptably high incidence. None of the 125 deaths was caused by fluconazole. Although contraindicated for vaginal candidiasis in pregnancy, fluconazole was taken by 289 women at some time during the months before or during pregnancy; a follow-up study by questionnaire of the outcome of pregnancy showed fluconazole to be without harmful effect.
It is concluded that fluconazole is a well tolerated drug in the treatment of vaginal candidiasis and is associated with very few adverse effects.
Similar content being viewed by others
References
Brammer KW (1989) Clinical experience with fluconazole in hospital practice. In: Richardson RG (ed) Fluconazole and its role in vaginal candidiasis. Royal Society of Medicine Services International Congress and Symposium Series No. 160. Royal Society of Medicine Services, London, pp 29–31
Multicentre Study Group (1988) Treatment of vaginal candidiasis with a single oral dose of fluconazole. Eur J Clin Microb Infect Diseases 7: 364–367
Kutzer E, Oittner R, Leodolter S, Brammer KW (1988) A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial. Eur J Obstet Gynaecol Reprod Biol 29: 305–313
Report of an International Multicentre Trial (1989) A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Br J Obstet Gynaecol 96: 226–232
Janssen PAJ, Symoens JE (1983) Hepatic reactions during ketoconazole treatment. Am J Med 74: 80–85
Hawkins Van Tyle J (1984) Ketoconazole. Pharmacotherapy 4: 343–373
Shaw JTB, Tarbit MH, Troke PF (1987) Cytochrome P-450 mediated sterol synthesis and metabolism: differences in sensitivity to fluconazole and other azoles. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of anti-fungal agents. Prous, Barcelona, pp 125–139
Humphrey MJ, Jevons S, Tarbit MH (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 28: 648–653
Inman WHW, Kubota K, Pearce GL, Wilton LV (1993) Fluconazole PEM Report No. 3. Drug Safety Research Unit, Southampton
Rubin PC, Wilton LV, Inman WHW (1992) Fluconazole and pregnancy: results of a prescription-event monitoring study, I. Int J Gynecol Obstetrics. 37 [Suppl]: 25–27
Matheson I, Soderman P, The Collaborative Group on Drug Use in Pregnancy (1989) Drug use in pregnancy. Preliminary results from Norway and Sweden (abstract). Eur J Clin Pharmacol 36: A 111
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inman, W., Pearce, G. & Wilton, L. Safety of fluconazole in the treatment of vaginal candidiasis. Eur J Clin Pharmacol 46, 115–118 (1994). https://doi.org/10.1007/BF00199872
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199872